These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 34439389)

  • 1. Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer.
    Wandmacher AM; Letsch A; Sebens S
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Pancreatic Ductal Adenocarcinoma Treatment.
    Anderson EM; Thomassian S; Gong J; Hendifar A; Osipov A
    Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities.
    Young K; Hughes DJ; Cunningham D; Starling N
    Ther Adv Med Oncol; 2018; 10():1758835918816281. PubMed ID: 30574212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer.
    Ostios-Garcia L; Villamayor J; Garcia-Lorenzo E; Vinal D; Feliu J
    World J Gastroenterol; 2021 Oct; 27(40):6775-6793. PubMed ID: 34790007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unveiling the immunosuppressive landscape of pancreatic ductal adenocarcinoma: implications for innovative immunotherapy strategies.
    Guo S; Wang Z
    Front Oncol; 2024; 14():1349308. PubMed ID: 38590651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic Cancer and Immunotherapy: A Clinical Overview.
    Timmer FEF; Geboers B; Nieuwenhuizen S; Dijkstra M; Schouten EAC; Puijk RS; de Vries JJJ; van den Tol MP; Bruynzeel AME; Streppel MM; Wilmink JW; van der Vliet HJ; Meijerink MR; Scheffer HJ; de Gruijl TD
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutic approach for advanced pancreatic adenocarcinoma.
    Kaur J; Mir T; Gill R; Duong J; Marcus S; Khan R
    Immunotherapy; 2021 Jun; 13(9):767-782. PubMed ID: 33910383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic Strategies in Pancreatic Cancer: Making
    Ullman NA; Burchard PR; Dunne RF; Linehan DC
    J Clin Oncol; 2022 Aug; 40(24):2789-2805. PubMed ID: 35839445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers and opportunities in pancreatic cancer immunotherapy.
    Ju Y; Xu D; Liao MM; Sun Y; Bao WD; Yao F; Ma L
    NPJ Precis Oncol; 2024 Sep; 8(1):199. PubMed ID: 39266715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy?
    Benkhaled S; Peters C; Jullian N; Arsenijevic T; Navez J; Van Gestel D; Moretti L; Van Laethem JL; Bouchart C
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC.
    Olaoba OT; Ligali FC; Alabi ZO; Akinyemi AO; Ayinde KS
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188483. PubMed ID: 33232723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components.
    Hsu SK; Jadhao M; Liao WT; Chang WT; Hung CT; Chiu CC
    Front Mol Biosci; 2022; 9():1020888. PubMed ID: 36299300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting both tumour-associated CXCR2
    Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
    Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer.
    Bazhin AV; Bayry J; Umansky V; Werner J; Karakhanova S
    Oncoimmunology; 2013 Sep; 2(9):e25736. PubMed ID: 24327934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Looking Beyond Checkpoint Inhibitor Monotherapy: Uncovering New Frontiers for Pancreatic Cancer Immunotherapy.
    Gupta K; Giurini EF; Ralph O; Pappas SG
    Mol Cancer Ther; 2024 Sep; ():. PubMed ID: 39311547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results.
    Chick RC; Gunderson AJ; Rahman S; Cloyd JM
    Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
    Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes.
    Alzhrani R; Alsaab HO; Vanamal K; Bhise K; Tatiparti K; Barari A; Sau S; Iyer AK
    Adv Ther (Weinh); 2021 Jun; 4(6):. PubMed ID: 34212073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.